AAC operates outpatient vascular access centres serving individuals with end-stage renal disease (ESRD), commonly known as kidney failure. TA completed a $130m minority leveraged recapitalisation of AAC in October 2006. The company is based in Glen Rock, Pennsylvania.
Todd Crockett, a managing director at TA Associates who was also on the AAC board, said, “During five years as a TA portfolio company, AAC grew from 14 to 29 freestanding interventional centres and increased procedure volumes by over four times.
“It has been gratifying to play a part in such significant growth, and we wish Raymond [Figueroa, CEO], the management team and the AAC board much continued success,” he added.
TA’s prior investments in the healthcare sector include Alere Medical, Amann Girrbach, AmeriChoice, CompBenefits, Dr Lal PathLabs, Invitrogen, MedSolutions, Millennium Laboratories, MQ Associates, National Imaging Associates, Triumph HealthCare and Twin Med.
Today Reuters reported that Kevin Landry, TA Associates’ chairman and one of its first employees, is currently fighting a serious illness which is hindering his activities within the $16bn firm.
Copyright © 2011 AltAssets